Overview
Yukihiro Shiga practices in Montreal, Canada. Shiga is rated as an Experienced expert by MediFind in the treatment of Spinocerebellar Degeneration and Corneal Dystrophy. Their top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Ganglion Cyst, Trabeculectomy, and Islet Cell Transplantation.
Their clinical research consists of co-authoring 83 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Spinocerebellar Degeneration and Corneal Dystrophy.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- GlaucomaShiga isElite. Learn about Glaucoma.
- Ocular Hypertension (OHT)
- Distinguished
- Ganglion CystShiga isDistinguished. Learn about Ganglion Cyst.
- Pigment-Dispersion SyndromeShiga isDistinguished. Learn about Pigment-Dispersion Syndrome.
- Advanced
- TrabeculectomyShiga isAdvanced. Learn about Trabeculectomy.
- Experienced
- BullaeShiga isExperienced. Learn about Bullae.
- HypertensionShiga isExperienced. Learn about Hypertension.
- Islet Cell TransplantationShiga isExperienced. Learn about Islet Cell Transplantation.
- NearsightednessShiga isExperienced. Learn about Nearsightedness.
- Optic Nerve AtrophyShiga isExperienced. Learn about Optic Nerve Atrophy.
- Retinal Vein OcclusionShiga isExperienced. Learn about Retinal Vein Occlusion.